Oxford university and AstraZeneca have begun work to produce an Omicron-targeted version of their coronavirus vaccine, The Financial Times reported on Tuesday.
When asked about Omicron, Sandy Douglas, a research group leader at Oxford, told FT, “Like with many previous variants of concern, and together with our partners AstraZeneca, we have taken preliminary steps in producing an updated vaccine in case it is needed.”
Read more